Pancreatic ductal adenocarcinoma, an aggressively invasive, treatment-resistant
malignancy and the fourth leading cause of cancer deaths in the United States, is usually …

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading
cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent …

Tumor maintenance relies on continued activity of driver oncogenes, although their rate-
limiting role is highly context dependent. Oncogenic Kras mutation is the signature event in …

Exosomes are cell-derived, phospholipid bilayer-enclosed vesicles that play important roles
in intercellular interactions and regulate many biological processes. Accumulating evidence …

Background: Hypoxia is a driving force in pancreatic-ductal-adenocarcinoma (PDAC)
growth, metastasis and chemoresistance. The muscle-isoform of lactate dehydrogenase …

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second cause of
cancer-related death in 2030. PDAC is the poorest prognostic tumor of the digestive tract …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death.
Despite improvements in the clinical management, the prognosis of PDAC remains dismal …

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related
deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ …

In this present work, we characterized the proteomes of pancreatic ductal adenocarcinoma
(PDAC) cell line PANC-1 and normal pancreatic duct cells by mass spectrometry using LTQ …

Background: Most of the patients with Pancreatic Ductal Adenocarcinoma (PDA) are not
eligible for a curative surgical resection. For this reason there is an urgent need for …